Boehringer Ingelheim Corporate News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Winners of the 2019 European PRRS Research Award
announcedBoehringer Ingelheim recognizes scientific excellence by awarding three research proposals with a funding of 25,000 euro each.The company sponsored the annual European PRRS Awards for the sixth time. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 7, 2019 Category: Research Source Type: news
Spiolto Respimat improves patient outcomes in COPD
New data reinforces benefits of Spiolto ® Respimat® in improving patient outcomesData supports the efficacy and safety profile of Spiolto ®Respimat®1Results from one study emphasise patient satisfaction and ease-of-use with Respimat ® inhaler2Two formative usability studies underscore the patient-centric design and enhanced usability of Respimat ® re-usable inhaler3 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 1, 2019 Category: Research Source Type: news
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc ® ParvoFLEX, a new porcine parvovirus vaccineReprocyc ® ParvoFLEX is the first subunit porcine parvovirus vaccine obtained through a baculovirus expression systemIt is mixable and can be applied together with Reprocyc PRRS EUVeterinarians and producers can now control two of the most prevalent reproductive diseases in swine herds simultaneously (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 1, 2019 Category: Research Source Type: news
PF_ILD_INBUILD_trial_meets_primary_endpoint
INBUILD ® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive phenotype1Phase III results published in the New England Journal of Medicine and to be presented at the European Respiratory Society (ERS) International Congress in Madrid, SpainRegulatory applications were recently submitted for this new indication with the FDA and EMA (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 30, 2019 Category: Research Source Type: news
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard ®, NexGard SPECTRA® and Broadline® approved by EMAThe marketing authorization variations were validated by the EU Commission decision1 and subsequently approved by EMANew indications were received as follows:NexGard ® and NexGard SPECTRA® for the treatment against Ixodes hexagonus tickNexGard SPECTRA ® for the prevention of establishment of thelaziosisBroadline ® for the treatment of adult and larval stages (L4) of Ancylostoma ceylanicum (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 27, 2019 Category: Research Source Type: news
world rabies day 2019
Boehringer Ingelheim donates vaccines to help fight rabiesThe company will donate 60,000 vaccine doses over three years to fight rabies in Puerto Rico It is part of a global campaign against a disease that claims an estimated 160 lives a day, half of whom are children1Rabies is present in more than 150 countries or regions1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 26, 2019 Category: Research Source Type: news
Collaboration for Novel Therapies for Retinal Diseases
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal DiseasesBoehringer Ingelheim strengthens its retinal disease pipeline portfolio with new co-development and license agreementThe partners aim to develop novel therapies with significantly reduced patient burden for eye diseases with limited or only insufficient treatment options using Inflammasome Therapeutics ’ intravitreal drug delivery technology Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other mileston...
Source: Boehringer Ingelheim Corporate News - September 20, 2019 Category: Research Source Type: news
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public healthThe center will be one of the largest biotechnology production sites for veterinary vaccines in EuropeThe company will invest 200 million euro into this high-tech complex, located near Lyon, France, and create around 100 skilled jobs (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 20, 2019 Category: Research Source Type: news
cardiovascular-risk-factors
Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factorsPost-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin based on the number of cardiovascular risk factor goals achieved.1Findings from the post-hoc analysis were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes.1 This analysis suggests that, independent of the number of risk factor goals achieved, empagliflozin demonstrated card...
Source: Boehringer Ingelheim Corporate News - September 19, 2019 Category: Research Source Type: news
Boehringer Ingelheim attends WVPAC 2019
Boehringer Ingelheim showcases its leading avian vaccines and services at WVPAC 2019Boehringer Ingelheim continues to lead1 the hatchery vectored vaccine market worldwide with VAXXITEK® and NEWXXITEK®Through its Vaccination Technologies and Services (VTS), the company continues to focus on innovation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 12, 2019 Category: Research Source Type: news
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev ® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILDInterstitial lung disease (ILD) is the leading cause of death among people with systemic sclerosis (SSc) or scleroderma3 Approval is based on results from the Phase III SENSCIS ® study, the largest randomized controlled trial in SSc-ILD patientsRegulatory review of the additional indication in other countries is still ongoingOfev ® (nintedanib) is already approved in the U.S. and more than 70 countries for the treatment of idiopathic pulmonary fibrosis (IPF) ...
Source: Boehringer Ingelheim Corporate News - September 9, 2019 Category: Research Source Type: news
Expansion of KRAS Cancer Program with MEK Inhibitor
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin ’s Clinical Stage MEK Inhibitor CompoundBoehringer Ingelheim strengthens its pipeline portfolio for patients with gastrointestinal and lung cancers with this new licensing, development and commercialization agreementLupin ’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s emerging KRAS inhibitor pipeline to address KRAS-driven cancersLupin to receive a $20 million upfront payment with potential total milestones of more than $700 million and royalties on the sales of the product (Source: Boehri...
Source: Boehringer Ingelheim Corporate News - September 4, 2019 Category: Research Source Type: news
RE-SPECT-CVT-Study-data-published
Results from RE-SPECT CVT ® published - first trial of NOAC in cerebral venous thrombosisStudy published in JAMA Neurology investigated Pradaxa ® (dabigatran etexilate) in patients with cerebral venous and dural sinus thrombosis (CVT)First exploratory study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this populationThe study is part of Boehringer Ingelheim ’s commitment to advancing thrombosis care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 4, 2019 Category: Research Source Type: news
Collaboration with Zealand Pharma Advances to Phase II
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/DiabetesThe dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim ’s pipeline portfolio in obesity and diabetesThe Phase 2 trial for BI 456906 is expected to be initiated in late 2019 and will trigger a EUR 20 million milestone payment to Zealand Pharma out of total outstanding potential milestone payments of EUR 365 million and high single to low double digit royalties on future sales (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 3, 2019 Category: Research Source Type: news
RE-LY-trial-publication-10-year-anniversary
Anniversary of the pivotal RE-LY ® trial marks a decade of innovation for stroke prevention in AF patients10 years ago, RE-LY ® marked the first time a randomised trial showed that a non-vitamin K antagonist oral anticoagulant (NOAC) was safer and at least as effective as warfarin for stroke prevention in atrial fibrillation (SPAF)1-3First major scientific advancement in anticoagulation care in over fifty yearsOver 100,000 patients have been included in the RE-VOLUTION study programme worldwide,4 and research into dabigatran etexilate continues (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 30, 2019 Category: Research Source Type: news
